Neurohormonal Inhibition and Hemodynamic Unloading During Prolonged Inhibition of ANF Degradation in Patients With Severe Chronic Heart Failure

No abstract is available for this paper.

• Publication year

  1992

• Venue

  Circulation

• Publication date

  1992-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/01.CIR.86.4.1089PMID 1394917
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thiorphan-induced natriuresis in volume-expanded rats: roles of endogenous atrial natriuretic factor and kinins.

  1991cited by this paper
• Chronic vs. acute hemodynamic effects of atrial natriuretic factor in conscious rats.

  1991cited by this paper
• Enhanced cardiac angiotensinogen gene expression and angiotensin converting enzyme activity in tachypacing-induced heart failure in rats

  1991cited by this paper
• Mechanisms Involved in the Response to Prolonged Infusion of Atrial Natriuretic Factor in Patients With Chronic Heart Failure

  1991cited by this paper
• Release of ANF, proANF 1-98, and proANF 31-67 from isolated rat atria by atrial distension.

  1991cited by this paper
• The atriopeptidase inhibitor (+/-) candoxatrilat reduces the clearance of atrial natriuretic factor in both intact and nephrectomized rats: evidence for an extrarenal site of action.

  1991cited by this paper
• Atrial Natriuretic Factor‐Potentiating and Antihypertensive Activity of SCH 34826: An Orally Active Neutral Metalloendopeptidase Inhibitor

  1990cited by this paper
• Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure.

  1990cited by this paper
• Rapid receptor-mediated catabolism of 125I-atrial natriuretic factor by vascular endothelial cells.

  1990cited by this paper
• Inhibitors of ANF metabolism. Potential therapeutic agents in cardiovascular disease.

  1990cited by this paper
• Atrial Natriuretic Factor Attenuates Sympathetic Reflexes During Lower Body Negative Pressure in Normal Men

  1990cited by this paper
• Atrial natriuretic peptide augments forearm capillary filtration in humans.

  1990cited by this paper
• Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects.

  1990cited by this paper
• Inhibition of the metabolism of atrial natriuretic factor causes diuresis and natriuresis in chronic heart failure.

  1990cited by this paper
• ANF disappearance and tissue distribution in rats.

  1990cited by this paper
• Diverse biological actions of atrial natriuretic peptide.

  1990cited by this paper
• The atriopeptidase inhibitor UK 69,578 increases atrial natriuretic factor and causes a natriuresis in normal humans.

  1990cited by this paper
• Possible regulation of atrial natriuretic factor by neutral endopeptidase 24.11 and clearance receptors.

  1990cited by this paper
• Protection of atrial natriuretic factor against degradation: diuretic and natriuretic responses after in vivo inhibition of enkephalinase (EC 3.4.24.11) by acetorphan.

  1989cited by this paper
• UK-69,578, a novel inhibitor of EC 3.4.24.11 which increases endogenous ANF levels and is natriuretic and diuretic.

  1989cited by this paper
• The N-terminus and a 4,000-MW peptide from the midportion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure.

  1989cited by this paper
• Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones 1

  1989cited by this paper
• Potentiation of the Depressor Responses to Atrial Natriuretic Peptides in Conscious SHR by an Inhibitor of Neutral Endopeptidase

  1989cited by this paper
• Sympathoadrenal inhibition by atrial natriuretic peptide is not attenuated during development of congestive heart failure in dogs.

  1989cited by this paper
• Atrial natriuretic peptide reverses angiotensin-induced venoconstriction in dogs.

  1989cited by this paper
• Effects of UK 69 578: a novel atriopeptidase inhibitor.

  1989cited by this paper
• Atrial natriuretic peptide inhibits postural release of renin and vasopressin in humans.

  1988cited by this paper
• Function of neutral endopeptidase on the cell membrane of human neutrophils.

  1988cited by this paper
• Atrial natriuretic factor alters autonomic interactions in the control of heart rate in conscious rats.

  1988cited by this paper
• Hemodynamic, renal and endocrine effects of atrial natriuretic peptide infusion in severe heart failure.

  1988cited by this paper
• Contribution of the kidney to metabolic clearance of atrial natriuretic peptide.

  1988cited by this paper
• Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption

  1987cited by this paper
• Inhibition of the firing of vasopressin neurons by atriopeptin

  1987cited by this paper
• Attenuation of Reflex Forearm Vasoconstriction by α‐Human Atrial Natriuretic Peptide in Men

  1987cited by this paper
• Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: beneficial effects on left ventricular function.

  1987cited by this paper
• The hydrolysis of alpha-human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11.

  1987cited by this paper
• Inhibition of sympathoadrenal activity by atrial natriuretic factor in dogs.

  1987cited by this paper
• Actions of atrial natriuretic peptides on the kidney.

  1987cited by this paper
• Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo.

  1987cited by this paper
• Atrial natriuretic factor (ANF) inhibits the growth and the secretory activity of rat adrenal zona glomerulosa in vivo.

  1987cited by this paper
• Prolonged administration of human atrial natriuretic peptide in healthy men: evanescent effects on diuresis and natriuresis.

  1986cited by this paper
• Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion.

  1986cited by this paper
• Four‐Hour Infusions of Synthetic Atrial Natriuretic Peptide in Normal Volunteers

  1986cited by this paper
• Postsynaptic alpha 1- and alpha 2-adrenergic receptors in adrenergic control of capacitance vessel tone in vivo.

  1986cited by this paper
• Activation of vagal depressor reflexes by atriopeptins inhibits renal sympathetic nerve activity.

  1986cited by this paper
• Blood levels and renal effects of atrial natriuretic peptide in normal man.

  1986cited by this paper
• In vivo atrial peptide-venodilation: minimal potency relative to nitroglycerin in dogs.

  1986cited by this paper
• Atrial natriuretic peptide inhibits renin release from juxtaglomerular cells by a cGMP-mediated process.

  1986cited by this paper
• An immunoradiometric assay for endopeptidase-24.11 shows it to be a widely distributed enzyme in pig tissues.

  1985cited by this paper
• Stimulation of peritoneal synthesis of vasoactive prostaglandins during peritonitis in patients on continuous ambulatory peritoneal dialysis

  1985cited by this paper
• Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis.

  1985cited by this paper
• Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure

  1985cited by this paper
• Kinin-induced prostaglandin synthesis by renal papillary collecting tubule cells in culture.

  1981cited by this paper
• Haemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure.

  1980cited by this paper
• Renal potassium transport: contributions of individual nephron segments and populations.

  1978cited by this paper
• Use of diuretics in renal disease.

  1970cited by this paper
• Mechanism of natriuretic action of bradykinin.

  1969cited by this paper
• Postsynaptic at-and a 2-Adrenergic Receptors in Adrenergic Control of Capacitance Vessel Tone in Vivo

  year unknowncited by this paper

• Advances in Cardiovascular Pharmacotherapy. VI. Sacubitril-Valsartan, An Angiotensin Receptor-Neprilysin Inhibitor.

  2025cites this paper
• Addition of Sacubitril/Valsartan to Mineralocorticoid Receptor Antagonist Therapy in Primary Aldosteronism: Effects on Plasma Aldosterone Concentration and Plasma Renin Activity

  2024cites this paper
• Neprilysin Inhibitors in Heart Failure

  2022cites this paper
• Mechanisms of current therapeutic strategies for heart failure: more questions than answers?

  2022cites this paper
• Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review

  2021influential citation
• Toward a New Paradigm for Targeted Natriuretic Peptide Enhancement in Heart Failure

  2021cites this paper
• Inhibitors of Neutral Peptidase

  2021cites this paper
• Acute Hemodynamic Effects of Sacubitril-Valsartan In Heart Failure Patients Receiving Intravenous Vasodilator and Inotropic Therapy: Acute Hemodynamic Effects of ARNI Therapy in Low Cardiac Output.

  2020cites this paper
• The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan

  2017cites this paper
• Neprilysin Inhibition and the Treatment of Heart Failure: Recent Steps in the Right Direction

  2017cites this paper
• Long-term neprilysin inhibition — implications for ARNIs

  2017cites this paper
• Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition.

  2017cites this paper
• Potential Expanded Indications for Neprilysin Inhibitors

  2017cites this paper
• A Test in Context: Neprilysin: Function, Inhibition, and Biomarker.

  2016cites this paper
• Neurohormonal Blockade in Heart Failure.

  2016cites this paper
• The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.

  2015cites this paper
• in Human Heart Failure Effect of Atrial Natriuretic Peptide on Muscle Sympathetic Activity and Its Reflex Control

  2013cites this paper
• Pathophysiology of Heart Failure

  2012cites this paper
• Fasidotril: The First Dual Inhibitor of Neprilysin and ACE

  2006cites this paper
• Chapter 71 – Vasopeptidase Inhibitors

  2005cites this paper
• Neurohormonal inhibition in heart failure: insights from recent clinical trials.

  2005cites this paper
• Endocrine and paracrine aspects of vascular control : the effects of natriuretic peptides on human capacitance in health and chronic heart failure

  2004influential citation
• Pharmakologische Grundlagen der medikamentsen antihypertensiven Therapie

  2004cites this paper
• Effects of Exogenous and Endogenous Natriuretic Peptides on Forearm Vascular Function in Chronic Heart Failure

  2004cites this paper
• Current and newer approaches in the drug treatment of congestive heart failure

  2004cites this paper
• Role of natriuretic peptides in regulation of conduit artery distensibility.

  2004cites this paper
• Modulation of the natriuretic peptide system in heart failure: from bench to bedside?

  2003cites this paper
• Combination of drugs acting on the natriuretic system and the renin-angiotensin system in heart failure

  2003cites this paper
• Mechanisms of renal hyporesponsiveness to ANP in heart failure

  2003cites this paper
• BNP and congestive heart failure

  2003cites this paper
• Cardioprotective effects of vasopeptidase inhibitors.

  2002cites this paper
• Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)

  2002cites this paper
• BNP and congestive heart failure.

  2002cites this paper
• Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction.

  2001cites this paper
• The Impact of Cardiac Natriuretic Peptide Determination on the Diagnosis and Management of Heart Failure

  2001cites this paper
• Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase.

  2001cites this paper
• Fonction endocrine du cœur

  2001cites this paper
• Vasopeptidase inhibitors.

  2001cites this paper
• Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin.

  2001cites this paper
• Neutral Peptidase Inhibitors

  2001cites this paper
• Omapatrilat: Neurohormonal and Pharmacodynamic Profile When Administered with Furosemide

  2001cites this paper
• Vasodilators in the treatment of pediatric heart failure.

  2000cites this paper
• Mechanisms of Disease

  2000cites this paper
• Short-term effects of ecadotril in dogs with induced congestive heart failure.

  2000cites this paper
• Vasopeptidase inhibition

  2000cites this paper
• Mechanisms involved in the hemodynamic alterations in congestive heart failure as a basis for a rational pharmacological treatment.

  2000cites this paper
• Sympathetic responses to atrial natriuretic peptide in patients with congestive heart failure.

  2000cites this paper
• [Enkephalin catabolism inhibitors and antalgics of the future: from preclinical research to clinical trials].

  1999cites this paper
• Effect of atrial natriuretic peptide on muscle sympathetic activity and its reflex control in human heart failure.

  1999cites this paper
• Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure.

  1999cites this paper
• Pharmacodynamic effects of dual neutral endopeptidase–angiotensin‐converting enzyme inhibition versus angiotensin‐converting enzyme inhibition in humans

  1999cites this paper
• Enhanced natriuretic response to neutral endopeptidase inhibition in heart-transplant recipients.

  1999cites this paper
• Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction.

  1999cites this paper
• Effects of atrial natriuretic peptide on left ventricular performance in conscious dogs before and after pacing-induced heart failure.

  1999cites this paper
• Potential future therapies: natriuretic peptides.

  1999cites this paper
• Novel Neurohormonal Modulators in Cardiovascular Disorders

  1999cites this paper
• Outpatient management of congestive heart failure.

  1998cites this paper
• Influence of age on neurohormonal activation and prognosis in patients with chronic heart failure.

  1998cites this paper
• The kidney in cardiac failure: today’s perspective

  1998cites this paper
• Natriuretic peptides.

  1998cites this paper
• N ATRIURETIC P EPTIDES

  1998cites this paper
• Clearance receptors and endopeptidase : equal role in natriuretic peptide metabolism in heart failure

  1997cites this paper
• Current and newer approaches in the drug treatment of congestive heart failure.

  1997cites this paper
• Cardiac hormones: diagnostic and therapeutic potential.

  1997cites this paper
• The kidney in heart failure: Vasodilator‐natriuretic systems

  1997cites this paper
• The natriuretic-peptide family.

  1997cites this paper
• Chapter IIIB – Special Diuretics

  1997cites this paper
• Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure.

  1997cites this paper
• Effect of prolonged inhibition of neutral endopeptidase on cardiac hypertrophy in rats with myocardial infarction

  1996cites this paper
• Renal effects of concurrent E‐24.11 and ACE inhibition in the aorto‐venocaval fistula rat

  1996cites this paper
• Long-term angiotensin-converting enzyme inhibition with high-dose enalapril retards nitrate tolerance in large epicardial arteries and prevents rebound coronary vasoconstriction in vivo.

  1996cites this paper
• Comparison of chronic neutral endopeptidase inhibition and furosemide in an ovine model of heart failure.

  1996cites this paper
• Effects of angiotensin-converting enzyme and neutral endopeptidase inhibitors: influence of bradykinin.

  1996cites this paper
• Suppression of atherosclerotic changes in cholesterol-fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11 (EC 3.4.24.11).

  1996cites this paper
• Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure

  1996cites this paper
• The renin-angiotensin-aldosterone system and the cardiac natriuretic peptides

  1996cites this paper
• Neutral endopeptidase 24.11 in neutrophils modulates protective effects of natriuretic peptides against neutrophils-induced endothelial cytotoxity.

  1996cites this paper
• Dissociation of coronary vascular tolerance and neurohormonal adjustments during long-term nitroglycerin therapy in patients with stable coronary artery disease.

  1996cites this paper
• Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.

  1996cites this paper
• New drugs in the treatment of heart failure.

  1995cites this paper
• The role of neutral endopeptidase in dogs with evolving congestive heart failure.

  1995cites this paper
• Renal response to candoxatrilat in patients with heart failure.

  1995cites this paper
• Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, 1994: NEW DRUGS IN THE TREATMENT OF HEART FAILURE

  1995cites this paper
• Peptides natriurétiques et inhibition de l'endopeptidase neutre: FACTEUR AURICULAIRE NATRIURÉTIQUE

  1995cites this paper
• Section Review: Cardiovascular & Renal: Changing insights in the drug treatment of congestive heart failure

  1995cites this paper
• Plasma neuro-endocrine activity in very elderly subjects and patients with and without heart failure.

  1995cites this paper
• Acute hemodynamic effects of combined inhibition of neutral endopeptidase and angiotensin converting enzyme in spontaneously hypertensive rats

  1995cites this paper
• Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction.

  1995cites this paper
• Mercaptoacyl dipeptides as dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. Preliminary structure-activity studies

  1994cites this paper
• Pharmacotherapy of congestive heart failure

  1994cites this paper
• Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.

  1994cites this paper
• Pharmacotherapy of congestive heart failure. Currently used and experimental drugs.

  1994cites this paper
• Mechanisms underlying the augmented responses of deoxycorticosterone acetate‐salt hypertensive rats to neutral endopeptidase inhibitors

  1994cites this paper
• The natriuretic peptides in heart failure

  1994cites this paper
• Patterns of systemic oxygen utilization in cardiac ischemic syndromes: oxygen utilization in cardiac ischemia.

  1994cites this paper
• Medical Advances in the Treatment of Congestive Heart Failure

  1993cites this paper
• Cardiac natriuretic peptides in heart failure.

  1993cites this paper
• Combined inhibition of neutral endopeptidase and angiotensin converting enzyme in cardiomyopathic hamsters with compensated heart failure.

  1993cites this paper
• Prognostic significance of N-terminal pro-atrial natriuretic factor (1-98) in acute myocardial infarction: comparison with atrial natriuretic factor (99-126) and clinical evaluation.

  1993cites this paper
• Clinical potential of endopeptidase-24.11 inhibitors in cardiovascular disease.

  1993cites this paper